DDInter675 DDInter39
Esmolol, commonly marketed under the trade name Brevibloc, is a cardioselective beta-1 receptor blocker. It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing activities at recommended therapeutic doses. It works by blocking beta-adrenergic receptors in the heart, which leads to decreased force and rate of heart contractions. Esmolol prevents the action of two naturally occurring substances: epinephrine and norepinephrine. The FDA withdrew its approval for the use of all parenteral dosage form drug products containing esmolol hydrochloride that supply 250 milligrams/milliliter of concentrated esmolol per 10-milliliter ampule. Other esmolol formulations are still available for use.
Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC cells. Inhibition of ALK prevents phosphorylation and subsequent downstream activation of STAT3 and AKT resulting in reduced tumour cell viability. Approved under accelerated approval in 2015, alectinib is indicated for use in patients who have progressed on or were not tolerant of crizotinib, which is associated with the development of resistance.
Esmolol {u} (Compound) resembles {v} (Compound) Acebutolol
Acebutolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alectinib
Esmolol {u} (Compound) resembles {v} (Compound) Metoprolol
Metoprolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alectinib
Esmolol {u} (Compound) resembles {v} (Compound) Acebutolol
Acebutolol {u} (Compound) resembles {v} (Compound) Metoprolol
Metoprolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alectinib
Esmolol {u} (Compound) resembles {v} (Compound) Metoprolol
Metoprolol {u} (Compound) resembles {v} (Compound) Acebutolol
Acebutolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alectinib
Esmolol {u} (Compound) resembles {v} (Compound) Propafenone
Propafenone {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Fingolimod {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alectinib
Esmolol {u} (Compound) downregulates {v} (Gene) RBM34
RBM34 {u} (Gene) is downregulated by {v} (Compound) Methoxsalen
Methoxsalen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alectinib
Esmolol {u} (Compound) resembles {v} (Compound) Acebutolol
Acebutolol {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Fingolimod {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alectinib
Esmolol {u} (Compound) resembles {v} (Compound) Propafenone
Propafenone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Quinine
Quinine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alectinib
Esmolol {u} (Compound) causes {v} (Side Effect) Inflammation
Inflammation {u} (Side Effect) is caused by {v} (Compound) Methoxsalen
Methoxsalen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alectinib
Esmolol {u} (Compound) resembles {v} (Compound) Metoprolol
Metoprolol {u} (Compound) resembles {v} (Compound) Pindolol
Pindolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alectinib
Esmolol (Compound) resembles Acebutolol (Compound) and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Esmolol (Compound) resembles Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Esmolol (Compound) resembles Acebutolol (Compound) and Acebutolol (Compound) resembles Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Esmolol (Compound) resembles Metoprolol (Compound) and Metoprolol (Compound) resembles Acebutolol (Compound) and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Esmolol (Compound) resembles Propafenone (Compound) and Propafenone may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Esmolol (Compound) downregulates RBM34 (Gene) and RBM34 (Gene) is downregulated by Methoxsalen (Compound) and Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Esmolol (Compound) resembles Acebutolol (Compound) and Acebutolol may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Esmolol (Compound) resembles Propafenone (Compound) and Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Esmolol (Compound) causes Inflammation (Side Effect) and Inflammation (Side Effect) is caused by Methoxsalen (Compound) and Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Esmolol (Compound) resembles Metoprolol (Compound) and Metoprolol (Compound) resembles Pindolol (Compound) and Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Alectinib